Compare with Royalty Pharma plc 5.9% 02-SEP-2054
Key terms
Profile
Sector
Health Technology
Industry
Pharmaceuticals: Major
Home page
ISIN
US78081BAS25
CUSIP
78081BAS2
FIGI
BBG01N5DKSH2
Identifiers
ISIN US78081BAS25
Royalty Pharma Plc engages in the provision of drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.
Sign up to see advanced bond data
Unlock important bond data including coupon rates, redemption details, risk assessments, and much more.